Cencora, Inc. (NYSE:COR) Shares Purchased by Axa S.A.

AXA S.A. grew its stake in Cencora, Inc. (NYSE:COR - Free Report) by 0.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 267,889 shares of the company's stock after purchasing an additional 2,413 shares during the period. AXA S.A. owned approximately 0.14% of Cencora worth $60,189,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. JFS Wealth Advisors LLC grew its stake in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Cencora in the fourth quarter worth $30,000. Kentucky Trust Co purchased a new stake in shares of Cencora during the fourth quarter worth $33,000. Householder Group Estate & Retirement Specialist LLC raised its stake in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares in the last quarter. Finally, WASHINGTON TRUST Co boosted its holdings in Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Morgan Stanley set a $288.00 price target on Cencora in a research report on Tuesday, April 15th. UBS Group raised their price objective on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Bank of America boosted their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. JPMorgan Chase & Co. raised their price target on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Finally, StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $290.00.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer now directly owns 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares in the company, valued at $89,027,442.53. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,223 shares of company stock valued at $13,580,967. Corporate insiders own 10.80% of the company's stock.

Cencora Price Performance

Shares of NYSE:COR traded up $13.23 on Wednesday, hitting $304.04. The company had a trading volume of 2,384,298 shares, compared to its average volume of 1,511,266. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The company has a market cap of $58.96 billion, a PE ratio of 43.25, a PEG ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $308.93. The business has a 50 day moving average of $274.32 and a 200 day moving average of $252.29.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.80 EPS. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.